Document:

Exhibit 10.40

 

SECOND AMENDMENT TO CREDIT AGREEMENT

 

This Second Amendment
(this “Second Amendment”), dated as of September 14, 2020, is entered into by and among ReShape
Lifesciences Inc., a Delaware corporation (the “Borrower”), and Armistice Capital Master Fund Ltd. (the
 “Lender”).

 

WHEREAS, the Borrower
and the Lender entered into a Credit Agreement dated as of March 25, 2020, which was amended on March 31, 2020 (as amended,
the “Agreement”), and a Registration Rights Agreement dated as of March 25, 2020 (the “RRA”).

 

WHEREAS, pursuant to
Section 9.1(a) of the Agreement and Section 6(f) of the RRA, the Agreement and the RRA, respectively, may be
amended with the written consent of the Borrower and the Lender.

 

WHEREAS, capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement.

 

NOW THEREFORE, for
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows:

 

1.            Amendment
of Definition of Delayed Draw Term Loan Commitment. The definition of “Delayed Draw Term Loan Commitment” set forth
in Section 1.1 (Definitions) of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Delayed Draw Term Loan
Commitment means $3,000,000, of which $1,000,000 is subject to outstanding Delayed Draw Term Loans extended prior to the date
of this Second Amendment.”

 

2.            Amendment
of Definition of Maturity Date. The definition of “Maturity Date” set forth in Section 1.1 (Definitions) of
the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Maturity Date means
(a) March 31, 2021 or (b) such earlier date on which the Commitments terminate pursuant to Section 8.”

 

3.            Amendment
to Section 2.1.2 of the Agreement. Section 2.1.2 (Delayed Draw Term Loan Commitments) is hereby amended to add the
following sentences at the end of such section:

 

“Lender agrees to make a Delayed Draw Term Loan
to Borrower on the date of this Second Amendment in an amount equal to $1,000,000. Accordingly, Borrower will be entitled to borrow
up to an additional $1,000,000 in Delayed Draw Term Loans after the date of this Second Amendment.”

 

4.            Amendment
of Definition of Filing Date in RRA. The definition of “Filing Date” set forth in Section 1 (Definitions)
of the RRA, dated March 25, 2020, between Borrower and Lender is hereby amended to replace the phrase “the 60th
calendar day following the date hereof” with “the 60th calendar day following the date of the Second Amendment.”

 

5.            Warrant
Issuance. As an inducement to Lender to enter into this Second Amendment and make the additional Delayed Draw Term Loans contemplated
hereby, Borrower will issue to Lender a warrant (the “Warrant”) to purchase an aggregate of 1,200,000 shares
of common stock of Borrower, par value $0.001 per share, at an exercise price equal to $3.25 per share, substantially in the form
of the Series G Common Stock Purchase Warrant issued by Borrower to Lender on March 25, 2020. The shares of Common Stock
issuable upon exercise of the Warrant will be considered “Warrant Shares” and, therefore, “Registrable Securities”
under the RRA.

 

     

     

    

 

6.             Miscellaneous.
  Except as expressly set forth hereunder, the terms and provisions of the Agreement and the RRA shall remain in full force and
effect after the execution of this Second Amendment and shall not be in any way changed, modified or superseded by the terms
set forth herein. This Second Amendment may be executed in several identical counterparts all of which shall constitute one
and the same instrument.

 

(Signature Page Follows)

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Second Amendment to Credit Agreement to be duly executed as of the day and year written above.

 

	BORROWER:	 	LENDER:
	 	 	 
	RESHAPE LIFESCIENCES INC.	 	ARMISTICE CAPITAL MASTER FUND LTD.
	 	 	 
	 	 	 
	By:	/s/ Barton P. Bandy	 	By:	/s/ Steven Boyd
	Name: Barton P. Bandy	 	Name: Steven Boyd
	Title: Chief Executive Officer	 	Title: CIO of Armistice Capital, LLC, the Investment ManagerExhibit 10.41

 

THIRD AMENDMENT TO CREDIT AGREEMENT

 

This Third Amendment
(this “Third Amendment”), dated as of December 16, 2020, is entered into by and among ReShape Lifesciences
Inc., a Delaware corporation (the “Borrower”), and Armistice Capital Master Fund Ltd. (the “Lender”).

 

WHEREAS, the Borrower
and the Lender entered into a Credit Agreement dated as of March 25, 2020, which was amended on March 31, 2020 and September 14,
2020 (as amended, the “Agreement”), and a Registration Rights Agreement dated as of March 25, 2020,
which was amended on September 14, 2020 (as amended, the “RRA”).

 

WHEREAS, pursuant to
Section 9.1(a) of the Agreement and Section 6(f) of the RRA, the Agreement and the RRA, respectively, may be
amended with the written consent of the Borrower and the Lender.

 

WHEREAS, capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement.

 

NOW THEREFORE, for
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows:

 

1.          Amendment
of Definition of Delayed Draw Term Loan Commitment. The definition of “Delayed Draw Term Loan Commitment” set forth
in Section 1.1 (Definitions) of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Delayed Draw Term Loan
Commitment means $7,000,000, of which $2,500,000 is subject to outstanding Delayed Draw Term Loans extended prior to the date
of this Third Amendment.”

 

2.          Amendment
to Section 2.1.2 of the Agreement. Section 2.1.2 (Delayed Draw Term Loan Commitments) is hereby amended to replace
the final two sentences of such section with the following:

 

“Lender agrees to make a Delayed Draw Term Loan
to Borrower on the date of this Third Amendment in an amount equal to $4,500,000. Accordingly, no additional Delayed Draw Term
Loans will be available after the date of this Third Amendment. Upon payment of the $4,500,000 referenced in this paragraph, the
total principal amount of Borrower’s debt to Lender shall be $9,500,000.”

 

3.          Amendment
of Definition of Filing Date in RRA. The definition of “Filing Date” set forth in Section 1 (Definitions)
of the RRA, dated March 25, 2020, between Borrower and Lender is hereby amended to replace the phrase “the 60th
calendar day following the date of the Second Amendment” with “the 60th calendar day following the date
of the Third Amendment.”

 

4.          Warrant
Issuance. As an inducement to Lender to enter into this Third Amendment and make the additional Delayed Draw Term Loans contemplated
hereby, Borrower will issue to Lender a warrant (the “Warrant”) to purchase an aggregate of 4,000,000 shares
of common stock of Borrower, par value $0.001 per share (the “Common Stock”), at an exercise price equal to
$3.50 per share, substantially in the form of the Series G Common Stock Purchase Warrant issued by Borrower to Lender on March 25,
2020 in connection with the execution of the Agreement and on September 14, 2020 in connection with the execution of the Second
Amendment to the Agreement. The shares of Common Stock issuable upon exercise of the Warrant will be considered “Warrant
Shares” and, therefore, “Registrable Securities” under the RRA. For the avoidance of doubt, the exercise price
of the Series G Common Stock Purchase Warrant issued by the Borrower to the Lender
on March 25, 2020, as amended, remains at $3.70 per share and the exercise price of the Series G Common Stock Purchase
Warrant issued by the Borrower to the Lender on September 14, 2020 remains at $3.25 per share.

 

     

     

    

 

5.          Miscellaneous.   Except
as expressly set forth hereunder, the terms and provisions of the Agreement and the RRA shall remain in full force and effect after
the execution of this Third Amendment and shall not be in any way changed, modified or superseded by the terms set forth herein.
This Third Amendment may be executed in several identical counterparts all of which shall constitute one and the same instrument.

 

(Signature Page Follows)

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Third Amendment to Credit Agreement to be duly executed as of the day and year written above.

	 	 	 	 	 
	BORROWER:	 	LENDER:
	 	 	 
	RESHAPE LIFESCIENCES INC.	 	ARMISTICE CAPITAL MASTER FUND LTD.
	 	 	 
	By:	/s/ Barton P. Bandy	 	By:	/s/ Steven Boyd
	Name: Barton P. Bandy 	 	Name: Steven Boyd 
	Title: Chief Executive Officer	 	Title: CIO of Armistice Capital, LLC, the Investment ManagerExhibit 10.42

 

CREDIT FACILITY AGREEMENT

 

This Credit Facility
Agreement (“Agreement”) is dated as of January 19, 2021 between ReShape Lifesciences Inc., a Delaware corporation
(“Borrower”), and Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (“Lender”).

 

A.          Borrower
has requested that Lender make available to Borrower a line of credit (the “LOC”) in a maximum principal amount
at any time outstanding of up to $15,000,000.

 

B.           Borrower
and Lender are also party to a Credit Agreement dated March 25, 2020, as amended (the “Existing Credit Agreement”)
and Guarantee and Collateral Agreement, dated March 25, 2020 (the “Security Agreement”).

 

C.           Borrower
and Lender both desire to memorialize the LOC pursuant to the terms and subject to the conditions set forth herein.

 

In consideration of
the mutual agreements herein contained, the parties hereto agree as follows:

 

Section 1.              Credit
Facility.

 

(a)  Subject
to the terms and conditions of this Agreement, Lender hereby agrees to extend a LOC of up to $15,000,000 (the “Advances”)
to Borrower from time to time from the date hereof until December 31, 2022. All Advances shall be made pursuant the terms
and obligations set forth in a promissory note in substantially the form attached hereto as Exhibit A (the
 “Note”). Borrower shall provide Lender with a reasonably detailed explanation of the principal purposes for
which the proceeds from any requested Advances are intended to be used and the approximate amount intended to be used for each
such purpose and, upon receipt of such explanation, Lender shall authorize and approve such Advance, which authorization and approval
will not be unreasonably withheld, delayed or conditioned.

 

(b)  At any
time after the initial Advance, if any, under this Agreement, Lender will be entitled to appoint a majority of the members of the
Board of Directors of Borrower or, if Lender exercises such right after the completion of the transactions contemplated by the
Merger Agreement (as defined below), a majority of the members of the Board of Directors of Obalon, which will then be Borrower’s
parent company, in each case subject to and in accordance with Borrower’s or, if applicable, Obalon’s certificate of
incorporation and bylaws, the Delaware General Corporation Law, the rules of the Nasdaq Stock Market (including Nasdaq Listing
Rule 5640), and any other applicable laws, rules and regulations. Lender may exercise such right by providing written
notice to Borrower. Following Borrower’s receipt of such notice from Lender, Borrower will reasonably cooperate with Lender
in order to cause Lender’s designated nominees, who must be reasonably acceptable to and approved by Borrower (such approval
not to be unreasonably withheld, delayed or conditioned), to be appointed to the Board of Directors of Borrower or, if applicable,
Obalon, as soon as reasonably practicable.

 

(c)  For the
purposes of the Advances, subject to the limitations, terms and conditions set forth in this Agreement and the Note, Borrower may,
from time to time, draw down, repay, and re-borrow on the Note, by giving notice to Lender of the amount to be requested to be
drawn down.

 

(d)  In order
to secure Borrower’s performance under the Note, Borrower agrees that the amount of any Advances under the LOC will be subject
to, and considered Secured Obligations under, the Security Agreement.

 

    - 1 -

     

    

 

(e)  Borrower
shall give written notice or telephonic notice (followed promptly by written confirmation thereof) to Lender of each proposed
borrowing of an Advance not later than 1:00 p.m. Eastern time at least three business days prior to the proposed
date of such borrowing. Each such notice shall be effective upon receipt by Lender, shall be irrevocable, and shall specify
the date and amount of such borrowing. Not later than 1:00 p.m. Eastern time on the date of a proposed Advance, Lender
shall pay over the requested Advance to Borrower on the requested borrowing date. Each borrowing shall be on a business day.
The minimum amount of any Advance shall be $500,000 and the maximum amount of any Advance shall be $1,250,000 (or if less,
the remaining undrawn amount of the LOC). After the date of the initial Advance, if any, under the LOC, any subsequent
Advance shall not be made sooner than 30 days after the date of any previous Advance without Lender’s prior written
consent.

 

(f)   This
Agreement, the Note and the Security Agreement, together with all of the other agreements, documents, and instruments heretofore
or hereafter executed in connection therewith or with the Advances to be made under this Agreement, as the same may be amended,
supplemented or modified from time to time, shall collectively be referred to herein as the “Loan Documents.”

 

Section 2.               Interest;
Maturity Date and Events of Default.

 

2.1.          Interest.
Borrower promises to pay interest on the unpaid principal amount of each Advance for the period commencing on the date of such
Advance until such Advance is paid in full at a rate per annum equal to the sum of the LIBOR Rate (as defined in the Existing Credit
Agreement) plus 2.5%; provided, that at any time an Event of Default exists, if elected by Lender, the interest rate corresponding
to each Advance shall be increased by two percentage points per annum effective as of the date upon which such Event of Default
(as defined below) first occurred or such later date determined Lender in writing. Interest shall be computed for the actual number
of days elapsed on the basis of a year of 365/366 days.

 

2.2.          Maturity
Date. All Advances shall be due on December 31, 2023.

 

2.3.          Events
of Default. Upon the occurrence of any of the following events (each, an “Event of Default”) Borrower shall
be deemed to be in default hereunder:

 

(a)  failure
by Borrower to pay when due any of the principal or accrued and unpaid interest of any Advance outstanding under any Note; or

 

(b)   Borrower
(i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of its
property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of
its property if such appointment is not terminated or dismissed within thirty (30) days, (iii) makes an assignment for the
benefit of creditors, (iv) is adjudicated as bankrupt or insolvent, (v) institutes any proceedings under the United States
Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting
the rights of creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take
advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency
petition filed against it, or (vi) becomes subject to any proceedings under the United States Bankruptcy Code or any other
federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally,
which proceeding is not dismissed within thirty (30) days of filing, or has an order for relief entered against it in any proceeding
under the United States Bankruptcy Code.

 

If an Event of Default
occurs, the amount of any Advance, including the outstanding principal and accrued and unpaid interest, under any Note shall become
immediately due and payable, and Borrower, upon the written request of Lender, shall immediately pay to Lender all such amounts.
Lender shall, following and during the continuance of an Event of Default, also have any other rights which Lender may have pursuant
to applicable law.

 

    - 2 -

     

    

 

Section 3.              Representations
and Warranties of Borrower.

 

Borrower represents
and warrants to Lender that:

 

3.1.         Organization.
Borrower is a corporation validly existing and in good standing under the laws of the State of Delaware. Borrower has the power
and authority to own its properties and assets and to carry out its business as now being conducted. Borrower has the power and
authority to execute, deliver and perform the Loan Documents to which it is a party, to borrow and guaranty money in accordance
with the terms thereof, to execute, deliver and perform its obligations under the Note and the other Loan Documents to which it
is a party and any other documents made by it as contemplated hereby, and to grant to the Lender liens and security interests in
the Collateral (as defined in the Security Agreement) as hereby contemplated.

 

3.2.         Authorization
and Approvals. All corporate action on the part of Borrower, its board of directors, and stockholders necessary for the (a) authorization,
execution, delivery and performance by it of the Loan Documents to which it is a party, and (b) the performance of its obligations
under the Loan Documents, has been taken or will be taken prior to this Agreement. This Agreement and the other Loan Documents,
when executed and delivered by Borrower, shall constitute the valid and binding obligations of Borrower, enforceable in accordance
with their respective terms.

 

3.3.         Litigation.
There is no litigation, arbitration or other proceedings taking place, pending or to the knowledge of Borrower threatened against
Borrower or any of its assets which questions the validity of this Agreement or the right of Borrower to enter into it or to consummate
the transactions contemplated hereby.

 

3.4.         No
Default. Borrower is not currently in default of any contractual obligation that would have a material adverse effect on Borrower’s
business, assets or financial condition.

 

3.5.         Pre-existing
Business Relationship; Experience. Borrower has a pre-existing business relationship with the Lender and has such knowledge
and experience in financial and business matters: (a) to be capable of evaluating the merits and risks of the LOC, (b) to
make an informed decision relating thereto, and (c) to protect its own interests in connection with the transaction contemplated
by this Agreement.

 

Section 4.             Representations
and Warranties of Lender.

 

Lender represents and
warrants to Borrower that:

 

4.1.         Requisite
Power and Authority. The Lender has all of the requisite power, authority, and capacity to execute, deliver, and comply with
the terms of this Agreement, and such execution, delivery, and compliance does not conflict with, or constitute a default under,
any instruments governing the Lender, any law, regulation or order, or any agreement to which the Lender is a party or by which
the Lender may be bound. All action on the Lender’s part necessary for the execution and delivery of this Agreement, the
consummation of the transactions contemplated hereby, and the performance of all obligations of the Lender hereunder has been taken.
This Agreement has been duly executed and delivered by the Lender.

 

4.2.         Pre-existing
Business Relationship; Experience. The Lender has a pre-existing business relationship with Borrower and has such
knowledge and experience in financial and business matters: (a) to be capable of evaluating the merits and risks of the
loan to Borrower, (b) to make an informed decision relating thereto, and (c) to protect its own interests in
connection with the transaction contemplated by this Agreement.

 

    - 3 -

     

    

 

Section 5.              Miscellaneous.

 

5.1.         Waiver
Under Credit Agreement and Outstanding Warrants.

 

(a)  Lender
hereby agrees that the transactions contemplated by the Agreement and Plan of Merger entered into by and among Borrower, Obalon
Therapeutics, Inc. (“Obalon”), and a wholly owned subsidiary of Obalon (the “Merger Agreement”),
including the Merger (as defined in the Merger Agreement), will not be deemed to be an Event of Default under the Existing Credit
Agreement and, accordingly, hereby agrees to waive its right to accelerate the payment of any amounts outstanding under the Existing
Credit Agreement in connection with the transactions contemplated by the Merger Agreement.

 

(b)  Lender
hereby agrees to waive its right to require Borrower to purchase any outstanding warrants to purchase capital stock of Borrower
held by Lender that may be triggered by the completion of the transactions contemplated by the Merger Agreement, including to the
extent the Merger (as defined in the Merger Agreement) may be considered a “Fundamental Transaction” under the terms
of such warrants that would otherwise, at the option of Lender, obligate Borrower to purchase such warrants by paying Lender an
amount of cash equal to the Black Scholes value of the remaining unexercised portion of such warrants on the date of the completion
of the Merger.

 

5.2.         Amendments.
No amendment, modification or waiver of, or consent with respect to, any provision of this Agreement or any of the other Loan Documents
shall in any event be effective unless the same shall be in writing and signed by Borrower and Lender and then any such amendment,
modification, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.
No delay or omission to exercise any right, power or remedy accruing to any party hereto shall impair any such right, power or
remedy of such party nor be construed to be a waiver of any such right, power or remedy, nor constitute any course of dealing or
performance hereunder.

 

5.3.         Notices.
All notices hereunder shall be in writing (including facsimile or other electronic (including .pdf) transmission) and shall be
sent to the applicable party at its address shown on Annex I or at such other address as such party may, by written notice
received by the other parties, have designated as its address for such purpose. Notices sent by facsimile or other electronic transmission
shall be deemed to have been given when sent; notices sent by mail shall be deemed to have been given three business days after
the date when sent by registered or certified mail, postage prepaid; and notices sent by hand delivery or overnight courier service
shall be deemed to have been given when received.

 

5.4.         Costs;
Expenses. If any action, suit, arbitration proceeding or other proceeding is instituted arising out of this Agreement, the
prevailing party shall recover all of such party’s costs, including the court costs and reasonable attorneys’ fees
incurred therein, including any and all appeals or petitions therefrom.

 

5.5.         Counterparts.
This Agreement may be executed in one or more counterparts (any of which may be delivered by fax or electronic mail transmission),
each of which will for all purposes be deemed to be an original and all of which will constitute the same instrument.

 

5.6.         Severability.
The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall
not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any
instrument or agreement required hereunder.

 

    - 4 -

     

    

 

5.7.          Entire
Agreement. This Agreement, together with the other Loan Documents, embodies the entire agreement and understanding among the
parties hereto and supersedes all prior or contemporaneous agreements and understandings of such parties, verbal or written, relating
to the subject matter hereof.

 

5.8.          Successors;
Assigns. This Agreement shall be binding upon and shall inure to the benefit of Borrower and Lender and their respective
successors and permitted assigns. No other party shall be a direct or indirect legal beneficiary of, or have any direct or indirect
cause of action or claim in connection with, this Agreement or any of the other Loan Documents.

 

5.9.          Governing
Law; Waiver of Jury Trial. This Agreement and each Note shall be governed by and construed in accordance with the laws of the
State of New York, without regard to conflict of laws principles. EACH OF BORROWER AND LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL
BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT, ANY NOTE, ANY OTHER LOAN DOCUMENT AND
ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH
OR THEREWITH OR ARISING FROM ANY LENDING RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES THAT ANY SUCH
ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

 

[Signature page follows]

 

    - 5 -

     

    

 

The parties hereto
have caused this Credit Facility Agreement to be duly executed and delivered by their duly authorized officers as of the date first
set forth above.

 

	 	RESHAPE LIFESCIENCES INC.,
	 	as Borrower
	 	 
	 	By:	/s/ Barton P. Bandy
	 	Name:	Barton P. Bandy
	 	Title:	Chief Executive Officer

 

	 	ARMISTICE CAPITAL MASTER FUND LTD.,
	 	as Lender
	 	 
	 	By:	/s/ Steven Boyd
	 	Name:	Steven Boyd
	 	Title:	CIO of Armistice Capital, LLC, the Investment Manager
	 	 	 

 

Signature Page to
Credit Facility Agreement

 

     

     

    

 

ANNEX I

 

Addresses

 

	 	 
	ReShape Lifesciences Inc.	 
	1001 Calle Amanecer	 
	San Clemente, California  92673	 
	Attention:	Bart Bandy, Chief Executive
Officer	 
	Telephone:	949-429-6680	 
	 	 
	Armistice Capital Master Fund Ltd,	 
	510 Madison Avenue, 7th Floor	 
	New York, New York 10022	 
	Attention:	Brian Kohn	 
	Telephone:	(212) 231-4930	 

 

     I-1

     

    

 

Exhibit A

 

Form of Note

 

	 	 	 	 
	$	 	 	 

 

The undersigned (“Borrower”),
for value received, promises to pay to Armistice Capital Master Fund Ltd. (the “Lender”) the aggregate unpaid
amount of all Advances made to Borrower by Lender pursuant to the Credit Facility Agreement referred to below, such principal amount
(which such amount may change over time pursuant to the Credit Facility Agreement) to be payable on the dates set forth in the
Credit Facility Agreement.

 

Borrower further promises
to pay interest on the unpaid principal amount of each Advance from the date of such Advance until such Advance is paid in full,
payable at the rate(s) and at the time(s) set forth in the Credit Facility Agreement. Payments of both principal and
interest are to be made in lawful money of the United States of America.

 

This Note evidences
indebtedness incurred under, and is subject to the terms and provisions of, the Credit Facility Agreement, dated as of January 19,
2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Facility
Agreement”; terms not otherwise defined herein are used herein as defined in the Credit Facility Agreement), between
Borrower and Lender, to which Credit Facility Agreement reference is hereby made for a statement of the terms and provisions under
which this Note may or must be paid prior to its due date or its due date accelerated.

 

This Note is made under
and governed by the laws of the State of New York applicable to contracts made and to be performed entirely within such State.

 

	 	RESHAPE LIFESCIENCES INC.
	 	 
	 	By:	                    
	 	Title:	 

 

     A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]